The randomized, placebo-controlled segment of the study showed that AD109 had a statistically significant and clinically meaningful difference from placebo after a single dose in the patients’ hypoxic burden.
Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, has named David P. White, MD, senior vice president of medical affairs. In this role, White will...
The patent provides intellectual property protection for oral formulations containing immediate-release and sustained-release layers of mazindol for NLS Pharmaceutics's Quilience.
Neurology Advisor interviews Aleksandra M. Kwasnik, MD, who co-authored a recent review on cannabinoids that was published in Current Pulmonology Reports.
Read MoreFT218 exhibited a pharmacokinetic profile that supported once-nightly dosing with adequate concentrations maintained throughout the night.
Read More
Responsibilities include leading the US commercial launch of the company’s lead program, once-nightly FT218, pending regulatory approval.
Read More
A total of 30 participants will be enrolled. Each participant will receive two different dose levels of AD109, and placebo, at bedtime.
Read MoreThe randomized, double-blind, placebo-controlled study is designed to assess the safety and efficacy of pitolisant in patients with PWS ages 6 to 65.
Read MoreKemPharm is investigating “KP1077” as a potential treatment for idiopathic hypersomnia (IH), a sleep disorder of excessive sleepiness.
Read MoreApnimed’s AD109 is dosed once-daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity.
Read More“Six out of 10 sodium oxybate-eligible patients are not going on therapy today, with twice-nightly dosing being the primary reason cited.”
Read More
Inhibiting the production of hydrogen sulfide in rats resulted normal breathing patterns becoming gasping patterns.
Read More
“There is significant need for greater awareness of idiopathic hypersomnia, which can severely impact a person’s daily life, and can often be misdiagnosed or undiagnosed over a substantial period of time.”
Read More
A patent proposes a new treatment method that targets the increased D1 receptor levels in RLS patients experiencing augmentation.
Read More
Emerging evidence suggests the gut microbiome can influence health and sleep quality through the brain-gut microbiome axis.
Read MoreThe expedited development plan includes a Phase 3 efficacy trial, which will be used to support the filing of an NDA for approval of AXS-12.
Read MoreIn the phase 1 trial, R-oxybutynin demonstrated a favorable PK profile and was well tolerated with no adverse events.
Read More